

TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

AN OPEN ACCESS JOURNAL FOCUSING ON CLOSING THE GAP BETWEEN "BENCH AND BEDSIDE"

Annual Report 2018

Editorial Office

Email: editor@tlcr.org





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

Outline of the Report

1. Basic Information
2. Editors-in-Chief
3. Editorial Board Members
4. Publication: Number, Article Types, Internationality
5. Pageviews
6. Readership
7. PMC Retrieval
8. Citations
9. Most Cited Articles
10. Most Read Articles
12. Focused Issues Published on TLCR
13. Upcoming Focused Issues and Guest Editors
14. The Publisher AME




TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

1. Basic Information

- Open Access
- Peer Reviewed
- Launched in March 2012
- Indexed by **SCIE(Web of Science), PubMed/PubMed Central, Scopus, Google Scholar, Medscape, Chemical Abstracts Service (CAS) Databases**
- Published quarterly (Mar. 2012-Dec 2012), and bimonthly (2013-)
- The first international journal focusing on closing the gap between “Bench and Bedside” in lung cancer and related thoracic diseases.





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

1. Basic Information

TLCR is the official publication of:

- General Hospital of Eastern Theater Command, Nanjing, China
- Society for Translational Medicine (STM), Hong Kong


TLCR is endorsed by:

- Spanish Lung Cancer Group (SLCG)
- Bonnie J. Addario Lung Cancer Foundation (ALCF)
- Brazilian Society of Thoracic Surgery (SBCT)



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

2. Editors-in-Chief



Yong Song, MD, PhD
General Hospital of Eastern
Theater Command, China



Caicun Zhou, MD, PhD
Shanghai Pulmonary
Hospital, China




Rafael Rosell, MD, PhD
Dexeus University
Institute, Spain



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

3. Editorial Board Members



94 members in total, Including:
One Honorary Editor-in-Chief
Three Editors-in-Chief
Three Associate Editors-in-Chief
One Editor Emeritus
Two Associate Editors
84 Editorial Board Members

Geographical Distribution of Editorial Board Members

Updated on Jan 07, 2019






TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

4. Publication: Number



Updated on Jan 07, 2019

Till Dec 31 2018, altogether **779** articles were published on TLCR.


The number of publication was increased from 2012-2014, yet it has kept a stability between 2014 and 2017, and has an obvious growth in 2018.



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

4. Publication: Diverse Article Types



TLCR embraces diverse article types to meet demands from international authors and readers. The major article types published in TLCR include Review Article, Editorial, Original Article/Expert Consensus/Guideline.


Updated on Jan 07, 2019



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

4. Publication: Internationality



In total, **803** Corresponding Authors from over **30** countries contributed to TLCR, with the majority from the **USA**.

Updated on Jan 7, 2019




TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

5. Pageviews

Explorer



From google analytics, Dec 31, 2018


According to the data collected from Google Analytics, pageviews to TLCR website has accumulated to **813,201** times till Dec. 31, 2018. Particularly, since the second half of 2017, TLCR's monthly pageviews has kept over **10,000** times. A year later, TLCR's monthly pageviews jumped to a new highlight—**15,000** times, and has keeping above it afterwards.





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH



6. Readership

According to the data from google analytics, over 39% readers are from USA, then followed by 7% from China and around 6% from UK.

Country	Acquisition			Behavior		
	Sessions	% New Sessions	New Users	Bounce Rate	Pages / Session	Avg. Session Duration
	338,261 % of Total: 100.00% (338,261)	77.98% Avg for View: 77.93% (0.06%)	263,780 % of Total: 100.06% (263,618)	78.93% Avg for View: 78.93% (0.00%)	1.63 Avg for View: 1.63 (0.00%)	00:01:19 Avg for View: 00:01:19 (0.00%)
1. United States	132,679 (39.22%)	82.69%	109,714 (41.59%)	84.69%	1.34	00:00:56
2. China	25,033 (7.40%)	57.38%	14,365 (5.45%)	61.00%	3.61	00:03:26
3. United Kingdom	20,188 (5.97%)	80.76%	16,303 (6.18%)	83.60%	1.33	00:00:56
4. India	16,519 (4.88%)	74.62%	12,326 (4.67%)	80.17%	1.70	00:01:35
5. Japan	13,654 (4.04%)	71.66%	9,784 (3.71%)	68.01%	1.90	00:01:36
6. Germany	9,982 (2.95%)	78.36%	7,822 (2.97%)	75.94%	1.53	00:01:06
7. Canada	9,751 (2.88%)	82.37%	8,032 (3.04%)	84.52%	1.35	00:00:53

From Google Analytics, Dec 31, 2018






TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

7. PMC Monthly Retrieval (Mar 2015-Dec 2018)



TLCR's monthly retrieval in PubMed Central is climbing from **3,604** retrievals in Mar 2015 to **45,535** retrievals in Mar 2018, with a steady increase of more than **10,000** retrievals over the same period.

Note: Data were collected from PubMed Central (Jan 7, 2019).






TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

8. Citations



According to the data from Web of Science™ core collection, TLCR has over **480** articles cited by SCIE-indexed journals, generating **4036** citations. Impressively, the citation of TLCR has been growing dramatically since 2016.

Note: Data were collected from Web of Science™ core collection on Jan 2, 2019.



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

9. Most Cited Articles(2012-2018)

Top 1. *Targeted therapy for non-small cell lung cancer: current standards and the promise of the future* (Times Cited: 169)

Contributors: Bryan A. Chan, Brett G.M. Hughes (Australia)

Full Text: <http://tlcr.amegroups.com/article/view/2699/4184>

Top 2. *Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities* (Times Cited: 121)

Contributors: Jeryl Villadolid, Asim Amin (USA)

Full Text: <http://tlcr.amegroups.com/article/view/4780/5460>

Top 3. *Global trends of lung cancer mortality and smoking prevalences* (Times Cited: 120)

Contributors: Farhad Islami, Lindsey A. Torre, Ahmedin Jemal (USA)

Full Text: <http://tlcr.amegroups.com/article/view/4894/5097>

Note: Data were collected from Web of Knowledge™ core collection on Jan 2, 2019.





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

9. Most Cited Articles(2012-2018)

Top 4. *Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review* (Times Cited: 108)

Contributors: Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao (Canada)

Full Text: <http://tlcr.amegroups.com/article/view/3501/4186>

Top 5. *Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer* (Times Cited: 64)

Contributors: Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto (Japan)

Full Text: <http://tlcr.amegroups.com/article/view/3750/4384>

Top 6. *Non-small cell lung cancer: current treatment and future advances* (Times Cited: 63)

Contributors: Cecilia Zappa, Shaker A. Mousa (USA)

Full Text: <http://tlcr.amegroups.com/article/view/8139/7308>

Note: Data were collected from Web of Knowledge™ core collection on Jan 2, 2019.





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

9. Most Cited Articles(2012-2018)

Top 7. *Recurrence after surgery in patients with NSCLC* (Times Cited: 53)

Contributors: Hidetaka Uramoto, Fumihiro Tanaka (Japan)

Full Text: <http://tlcr.amegroups.com/article/view/2053/3470>

Top 8. *Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer* (Times Cited: 51)

Contributors: Po Yee Yip (Australia)

Full Text: <http://tlcr.amegroups.com/article/view/3991/4385>

Top 9. *Lung cancer molecular epidemiology in China: recent trends* (Times Cited: 48)

Contributors: Caicun Zhou (China)

Full Text: <http://tlcr.amegroups.com/article/view/3143/3752>

Note: Data were collected from Web of Knowledge™ core collection on Jan 2, 2019.





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Most Read Articles

Top 1. *Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?* (Pageviews: 47,477)

Contributors: Yoshihisa Kobayashi, Tetsuya Mitsudomi (Japan)

Full text: <http://tocr.amegroups.com/article/view/1608/2332>

Top 2. *Targeted therapy for non-small cell lung cancer: current standards and the promise of the future* (Pageviews: 2237)

Contributors: Bryan A. Chan, Brett G.M. Hughes (Australia)

Full text: <http://tocr.amegroups.com/article/view/2699/4184>

Note: The pageviews is from the google analytics on Jan 10, 2019, with time frame between Jun 2017 and Dec 2018.



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Most Read Articles

Top 3. *Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer* (Pageviews: 2236)

Contributors: Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto (Japan)

Full text: <http://tlcr.amegroups.com/article/view/3750/4384>

Top 4. *Current state of immunotherapy for non-small cell lung cancer* (Pageviews: 1550)

Contributors: Jyoti Malhotra, Salma K. Jabbour, Joseph Aisner (USA)

Full text: <http://tlcr.amegroups.com/article/view/13072/10996>

Top 5. *Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review* (Pageviews: 1089)

Contributors: Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao (Canada)

Full text: <http://tlcr.amegroups.com/article/view/3501/4186>

Note: The pageviews is from the google analytics on Jan 10, 2019, with time frame between Jun 2017 and Dec 2018.






TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Focused Issues Published in 2017-2018



Vol 7, No 6 (December 2018): Current Knowledge and Future Perspectives on Tumor Mutational Burden in Non-small Cell Lung Cancer-Guest Editors: Marius Ilie, Paul Hofman

In the rapidly evolving landscape of emerging biomarkers for immunotherapy, tumor mutational burden (TMB) is very promising as a predictive biomarker and potentially could lead the way for precision immuno-oncology. In this context, this focused issue of Translational Lung Cancer Research (TLCR) aims to capture the progress, challenges, limitations and perspectives to understand the measurement methods and clinical significance of TMB in patients with lung carcinoma.

[Read More>>](#)



Vol 7, No 5 (October 2018): Malignant Pleural and Peritoneal Mesothelioma-Guest Editors: Paul Van Schil, Jan Van Meerbeeck

This focused issue is organized to provide a clear update on pleural and peritoneal mesothelioma, to stimulate further research and hopefully, to provide a better outcome for patients with this still dreadful disease.

[Read More>>](#)



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH



Vol 7, No 4 (August 2018): Lung Cancer in Never Smokers-Guest Editor: Adi F. Gazdar

This focused edition of the journal highlights lung cancer in never smokers. The five articles in this focused issue summarize the relevant information on five important issues about lung cancers arising in never smokers and demonstrate approaches for assessing the extent of smoke related damage in lung cancers.

[Read More>>](#)

We are grieved by the passing of Professor Adi F. Gazdar who has made outstanding contribution to the field of molecular pathology. We will never forget his contribution to our journal TLCR. Herein we pay our deep tribute to Professor Adi F. Gazdar and sincere condolence to his families.



TLCR


TRANSLATIONAL LUNG CANCER RESEARCH



Vol 7, No 3 (June 2018): Lung Cancer Screening-Guest Editors: Caroline Chiles, Reggie F. Munden

Although the primary results of the National Lung Screening Trial (NLST) were published only 7 years ago, lung cancer screening today is rapidly advancing (1). In this issue of Translational Lung Cancer Research (TLCR) dedicated to CT screening for lung cancer, we include reviews of many of those advances—some already in clinical use, and some still in development.

[Read More>>](#)



Vol 7, No 2 (April 2018): Proton Therapy in Non-small cell lung cancer- Guest Editors: Ramesh Rengan, Jing Zeng

Proton therapy is an important tool in the era of precision oncology, where the goal is for personalized radiation therapy that achieves the right dose to the tumor, with the minimum possible toxicity, and maximal efficacy. Proton therapy is not expected to be uniformly superior for all patients in all scenarios, but it is expected to provide dosimetric advantages that translate into superior clinical outcomes for the right patient, at the right time.

[Read More>>](#)



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH



Vol 7, No 1 (February 2018): Small Cell Lung Cancer: New Models, Markers and Beyond-Guest Editor: Peter Ujhazy

This series does not attempt to completely list all the recent progress in SCLC research that has been well covered elsewhere in recent reviews. Rather it focuses more in depth on a few critical developments that may lead to improved diagnosis and interventions for SCLC patients. The field is rapidly moving forward and we will hopefully see translation of these new discoveries into clinical practice soon.

[Read More>>](#)



Vol 6, No 6 (December 2017): Imaging- and blood-based biomarkers for lung cancer precision medicine-Guest Editor: Feng-Ming (Spring) Kong

This journal issue of *Translational Lung Cancer Research* will focus on the role of imaging and blood-based biomarkers for precision medicine, which may provide a unique angle of guidance on top of the knowledge provided by tissue biopsy for a more holistic view on the patient and lung cancer, aiming to achieve a new level of precision medicine.

[Read More>>](#)



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH



Vol 6, No 5 (October, 2017): Update on Pathology and Predictive Biomarkers of Lung Cancer-Guest Editor: Mari Mino-Kenudson

Lung cancer is the leading cause of cancer death worldwide and represents 19% of all cancer-related deaths. In the US, the majority, about 60% of patients, present with stage IV disease, and the 5-year overall survival (OS) rate is 4.5% for stage IV and 18% for all stages. Even those who presented with stage I tumors, 45% will die at 5 years. Thus, there have been multiple efforts to improve the survival of not only patients with advanced disease, but also those with early stage tumors. In this focused issue of Translational Lung Cancer Research, the above important topics are discussed in depth. Hopefully, the readers will enjoy the collection of timely articles and apply valuable pieces of information to their daily practice.

[Read More>>](#)



Vol 6, No 4 (August 2017): Current Knowledge and Future Perspectives on Circulating Tumor Cells in Lung Cancer-Guest Editors: Fiona Blackhall, Caroline Dive

This focused issue aims to capture the progress that has been made in the past decade to understand the biology and clinical significance of circulating tumour cells (CTCs) in patients with lung cancer. Crucially, understanding cancer evolution in lung cancer and its associated resistance to therapy can only be achieved with repeated sampling and analysis of the cancer. CTCs provide a readily obtained liquid biopsy and offer unprecedented potential to inform on new treatment strategies. Several platforms now exist for CTC isolation, enumeration and analysis.

[Read More>>](#)



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH



Vol 6, No 3 (June 2017): Malignant Pleural Mesothelioma: Updates and New Directions-Guest Editor: Chuong D. Hoang

The most common form of malignant mesothelioma is that affecting the pleura. Mesothelioma, despite being considered a relatively rare tumor, appears to be more common now reversing previous worldwide predictions of a disease plateau and eventual decreased burden. In fact, the future prevalence of this pleural cancer is predicted to be increasing, raising concerns for a serious burgeoning international public health problem (1). Several industrialized nations are still without country-wide, legislative total bans on the production and use of asbestos such as China, India and the United States.

[Read More>>](#)



Vol 6, No 2 (Apr 2017): Combining Radiation Therapy and Immunotherapy for Thoracic Malignancies-Guest Editors: Charles B. Simone II, Abigail T. Berman, Salma K. Jabbour

This focused issue of Translational Lung Cancer Research details the current pre-clinical and clinical evidence supporting the use of immunotherapy for the treatment of thoracic malignancies, including for NSCLC, SCLC, thymic malignancies, and malignant pleural mesothelioma, as well as for unique disease considerations such as oligometastases, recurrent tumors being treated with reirradiation, and patients receiving palliative radiotherapy.

[Read More>>](#)





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

Vol 6, No 1 (February 2017): Small Pulmonary Nodules-Guest Editors: Tangfeng Lv, Yong Song, Matthijs Oudkerk



Tangfeng Lv

General Hospital of Eastern
Theater Command, China



Yong Song

General Hospital of Eastern
Theater Command, China



Matthijs Oudkerk

University Medical Center Groningen,
the Netherlands





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

13. Upcoming Focused Issues and Guest Editors

Stereotactic body radiotherapy(SBRT) in lung cancer

Charles B. Simone II (Maryland Proton Treatment Center, USA)

Tobacco and lung cancer

Jacek Jassem(The Medical University of Gdansk, Poland)

What's New in Lung Radiation Oncology

Alexander V. Louie(Sunnybrook Health Sciences Centre, University of Toronto, Canada)

Drew Moghanaki (Emory School of Medicine, USA)

Houda Bahig (Centre Hospitalier de l'Université de Montréal, Canada)

Targeted Therapies in NSCLC: An Evolving Landscape

Lucio Crinò (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Italy)





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

13. Upcoming Focused Issues and Guest Editors

Mesothelioma: What We know and What We Do Not Know in 2020

Michele Carbone (University of Hawaii Cancer Center, USA)

New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies

Helmut H. Popper (Medical University of Graz, Austria)

Pending Topic

Sanja Dacic (University of Pittsburgh, USA)



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

13. Upcoming Focused Issues and Guest Editors

Genomic Marker-guided Therapy for Lung Cancer

Lauren Byers (MD Anderson Cancer Center, USA)

Multi-gene diagnostic in NSCLC

David M. Jablons (University of California at San Francisco, USA)

Pending Topic

Justin F. Gainor (Massachusetts General Hospital, USA)

Pending Topic

Patrick C. Ma (Cleveland Clinic, USA)

Pending Topic

Nagio Takigawa (Kawasaki Medical School, Japan)



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

14. Introduction of the Publisher AME

Our Publisher—

AME Publishing Company

www.amegroups.com

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world

- 60+ peer-reviewed journals
 - 11 indexed in SCIE
 - 18 indexed in PubMed/PMC/MEDLINE


- 110+ Medical Books
 - 50+ Medical Books in English
 - 50+ Medical Books in Chinese





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH



AME PUBLISHING COMPANY, EDITORIAL OFFICES

Email: hr@amegroups.com

